Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer Single Arm Exploratory Study
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Rivoceranib (Primary) ; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Feb 2017 Time frame of primary end point has been changed from Up to 1.5 years to 4 weeks.
- 15 Feb 2017 Planned primary completion date changed from 1 May 2018 to 1 Nov 2017.
- 01 Dec 2016 New trial record